Evidence map›Paper›PMID 20013007›Full record

Trial reportJournal of neural transmission (Vienna, Austria : 1996)2010

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Karla Eggert, Orjan Skogar, Khaled Amar, Liisa Luotonen, Mikko Kuoppamäki, Mika Leinonen, Helena Nissinen, Wolfgang Oertel

Abstract readClinical Trial, Phase IVMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of neural transmission (Vienna, Austria : 1996), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?Journal of neural transmission (Vienna, Austria : 1996) · 2012
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karla EggertDepartment of Neurology, Philipps-University Marburg, Marburg, Germany. eggert@med.uni-marburg.de
Orjan Skogar
Khaled Amar
Liisa Luotonen
Mikko Kuoppamäki
Mika Leinonen
Helena Nissinen
Wolfgang Oertel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study objective was to assess the efficacy, safety and feasibility of switching from levodopa/benserazide (LB) or levodopa/carbidopa (LC) to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) patients with wearing-off. This was a multicenter, open-label, 6-week study; the primary outcome was success rate based on the patient-assessed Clinical Global Impression of Change (P-CGI-C). Secondary outcomes included investigator-assessed CGI-C (I-CGI-C), change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS), motor/non-motor wearing-off symptoms and quality of life-visual analog scale (QoL-VAS). After switching to LCE, 77% of patients reported an 'improvement' (p < 0.0001 vs. patients reporting 'no change or worsening'). Significant improvements were seen in I-CGI-C, UPDRS and QoL-VAS, regardless of prior therapy. Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded. The data suggest that switching from LB/LC to LCE provided a significant benefit in PD patients with wearing-off.

Indexed as

AgedAntiparkinson AgentsBenserazideCarbidopaCatecholsDrug-Related Side Effects and Adverse ReactionsDyskinesiasFeasibility StudiesFemaleHumansLevodopaMaleNitrilesParkinson DiseaseSeverity of Illness IndexSurveys and QuestionnairesAntiparkinson AgentsBenserazideCarbidopaCatecholsentacaponeLevodopaNitriles

Identifiers

PMID20013007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.